Compare Amylx Pharmaceuticals Inc (AMLX) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Nutrien Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.12 (market cap $1.98B), while Nutrien Ltd trades at $67.1 (market cap $31.29B). The key difference: Nutrien Ltd is far larger — about 15.8× Amylx Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.36% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NTR | |
|---|---|---|
Market Cap | $1.98B | $31.29B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $83.94 |
52-Week Low | $7.64 | $53.64 |
Enterprise Value | $1.70B | $44.46B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Nutrien (NTR) trades at $65.43, up 1.33% today, with a neutral technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, driven by record potash volumes. The stock shows solid fundamentals with a P/E of 13.33 and ROE of 9.7%, though revenue has declined from 2022 peaks. A dividend of $0.55 per share is scheduled for July 2026, supporting income appeal.
Outlook remains positive with a consensus price target of $80.14, reflecting 22% upside potential. Risks include volatile fertilizer prices and geopolitical impacts on agriculture markets. Institutional sentiment is bullish, with 64% of analysts rating it Buy, but investors should monitor debt levels and global demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
